evipedia.ai
← Back to Review

Audit: QRS - Tea Tree Oil for Health & Longevity

Audit conducted on 21/08/2026 07:12 using AI4L / Opus 5

Iterations

Summary

Items Count
Total 93
Passed 83
Failed 0
N/A 10
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 All protocol figures (5% gel twice daily/12 weeks, 25% solution, 5% shampoo/three minutes), time-to-effect windows, benefit and risk headings, contraindications, interactions, markers and cadence trace to ER lines 372–378, 435, 338–346, 318–334, 467–485.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 “No established target” (marker_7_target) and “No documented interaction” / “No established interaction from topical use” (caution_items) mirror ER lines 475, 328, 332 verbatim.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Contraindications retain absolute force (“Ingestion, at any dose, in any dilution”); “Caution by convention only” is preserved rather than upgraded to a plain caution.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 stop_items map only to the ER avoid-list and the “Barrier-disrupting procedures” absolute contraindication; caution_items map only to ER interaction bullets; no Benefit- or Risk-Modifying Factor is surfaced as a gate.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 The QRS carries no PMIDs, NCT identifiers, author names or brand names.
1.6 The QRS does not introduce new attributions. 🟢 No attributions of any kind appear in the QRS.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Neutral, evidence-first register; British spellings (“sensitisation”, “decolonisation”, “oxidised”) carried over from the ER.
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢 Tiered benefits and risks plus concrete markers and targets give an actionable, non-alarmist frame.
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢 Protocol cells state what trials administered rather than instructing the reader.
2.4 The QRS avoids language that implies medical or clinical advice 🟢 No imperatives, no “should”, “recommend”, “advise” or “consult” anywhere in the document body.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 All cells are declarative statements of trial or ER content.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person pronouns present.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢 Technical terms retained (colophonium, Demodex, periodontal attachment) are the ER’s own and are unavoidable for the fact; nothing is gratuitously technical.
2.8 Information is presented in a concise and very compact manner 🟢 Every gate, benefit and risk item is a single short phrase; all mechanistic and effect-size material is stripped.
2.9 It DOES NOT address the reader directly 🟢 Confirmed: no “you”/”your” in the file.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢 Patch-test marker, mite counts, fungal culture and pocket-depth targets address a proactive, self-monitoring reader.
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Twice-daily 12-week and four-week regimens and clinic-based confirmatory testing are presented without hedging on effort.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢 No simplification to a general-consumer level; full monitoring panel retained.
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 at_a_glance states plainly that the oil “has no plausible longevity role”, the decisive framing for this audience.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 “longevity” used in the page title, header topic and at_a_glance; “anti-aging” does not appear.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢 “Ingestion”, “allergic contact dermatitis”, “ocular mucosa”, “systemic toxicity” used throughout; the plainer at_a_glance wording (“swallowing it is dangerous”) reproduces the ER Conclusion at line 511.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All fixed strings match the template byte-for-byte (lines 445, 484, 526, 557, 577, 618, 649, 653–655, 753).
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All 34 named template variables present; the repeatable marker_# and qualitative_item_# spans are expanded to marker_1–7 and qualitative_item_1–7.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 A structural diff against the template shows the only differences are variable payloads and the marker/qualitative row expansions; the website="evidence_review", website="audit" and website="full_review" spans and all CSS are untouched.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No source ER section that feeds the QRS is empty.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 “Standard acne protocol”, “Athlete’s foot protocol”, “Dandruff protocol” and all nine interaction labels reproduce the ER bold labels verbatim (ER lines 372–378, 318–334).
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Benefit and risk items reuse the ER sub-headings; monitoring markers reuse the ER biomarker column.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji characters present; the ER’s ⚠️ Conflicted markers are correctly dropped.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Every section is condensed to phrase-level entries; interaction parentheticals are trimmed to two example drugs and marker names shortened (e.g. “in petrolatum”, “(potassium hydroxide preparation)” dropped) to hold the budget.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Lines 2–14, immediately after <!doctype html> at line 1.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 Opening --- at line 3, closing --- at line 13.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in an HTML comment; no metadata value is repeated in the header, footer or body.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Only duration: "00:03" is quoted, correctly, because it contains a colon.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 Line 4: er_filename: tea_tree_oil_2026-0825-0544_Opus_ER.md.
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 Line 5: 26.7.02, matching the QRS.md version badge.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 Line 6: 2026-0821-0633, correct format.
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 Line 7: Opus.
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 Single word, no version.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 Line 8: Opus 5.
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 “Opus 5” — nickname plus version, no qualifier.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 Line 9 matches the actual filename on disk.
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Re-verified across all nine keys; no stray whitespace or quoting.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 Line 22: “Tea Tree Oil for Health & Longevity - Quick Reference Sheet”.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 Line 417: “Tea Tree Oil for Health & Longevity”.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 Line 421: “08/21/2026”, matching qrs_creation_date 2026-0821-0633.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 Line 425: “Opus 5”.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 Header contains only the title and the template subline; the ER’s “Also known as” line is not carried over.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Compresses ER lines 507–511: surface action, no longevity reach, acne as strongest case, allergy and ingestion as the harms.
7.2 [at_a_glance] is no longer than 60 words 🟢 52 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Each of the four sentences maps to a distinct sentence in the ER Conclusion (lines 507, 509, 511).
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 Plain vocabulary throughout (“plant oil”, “outer coats”, “lasting allergy”, “swallowing”); no acronyms.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No trial identifiers of any kind.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No numbers appear in the passage.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Sourced from the “Populations who should avoid Tea Tree Oil” list (ER lines 338–346) plus the absolute contraindication at line 336.
8.2 [stop_items] represent the Contraindications from the ER 🟢 All seven ER avoid-list entries are present, and the barrier-disrupting-procedure contraindication is folded into the eczema/open-wound item.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Seven <li> elements inside the stop_items span (lines 560–572).
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 ER rationales such as “because it creates a direct infant ingestion route” (line 343) are stripped; no dashes carry trailing clauses.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 “5%” patch-test concentration, “under 12”, “repeated leave-on”, “nipple or areolar”, “high-dose corticosteroids” and “at any concentration” all retained.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER uses no ranking notation in this section.
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢 The ER identifies seven such populations, and the section is correctly populated rather than empty.
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A The section is not empty.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All nine items map to ER lines 318–334.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 Nine of the ER’s ten interaction bullets are carried; “Barrier-disrupting procedures” (line 336) is correctly excluded because it appears as a contraindication.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Nine <li> elements inside the caution_items span (lines 580–608).
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Every ER clause after the em-dash (“additive irritation, dryness and peeling”, “because absorption is 1–4%”, etc.) is stripped; only the label, examples and the verdict word remain.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Each item retains two representative example drugs (e.g. “warfarin, amlodipine”, “clotrimazole, terbinafine”); none is dropped entirely.
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER uses no ranking notation in this section.
9.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢 The ER identifies ten interactions, and the section is correctly populated.
9.8 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A The section is not empty.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 Drawn from the ER “Therapeutic Protocol” bullets at lines 372–386.
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Acne (the ER’s High-tier benefit), athlete’s foot and dandruff (both Medium-tier) are selected over the Low-tier nail and contested eyelid protocols.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER describes seven distinct protocols, so all three sets are used.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All nine cells carry ER-derived content (lines 449–479); labels are the ER’s bold labels and values/subs carry the concentration, frequency and duration.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Acne, athlete’s foot and dandruff, all taken from ER line 435; the Low-tier six-month nail figure is correctly omitted.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Acne (High) first, then athlete’s foot and dandruff (both Medium, in ER order).
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER gives four distinct time-to-effect figures, so all three sets are used.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 “4 to 12 weeks / More slowly than benzoyl peroxide” (ER line 435) and the two four-week entries with their application details (ER lines 376, 378).
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER provides time-to-effect information at line 435.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 All twelve items reproduce the ER sub-headings from lines 156–228.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four spans present and populated (lines 528–550).
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 No magnitudes (OR 0.74, 41% improvement, 97.6%) or mechanisms carried over; each item is a bare noun phrase.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 The ER’s inline expansions (“methicillin-resistant Staphylococcus aureus…”, “tinea pedis”, “onychomycosis”) are stripped.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four benefit tiers carry items in the ER.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 All eight items reproduce the ER sub-headings from lines 252–300.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four spans present and populated (lines 620–643).
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Frequencies (0.1%–3.5%, 3.8%) and mechanisms are all stripped.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 The ER’s parenthetical glosses (“gynecomastia”, “premature thelarche”, “loss of muscle coordination”) are stripped.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four risk tiers carry items in the ER.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Taken from the ER “Monitoring Protocol & Defining Success” biomarker table (lines 467–475).
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All seven ER table rows appear as marker_1 through marker_7, with targets and rationales matching.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Lines 744–747 condense ER line 465: tolerance at 1 and 4 weeks, efficacy at 12 weeks and 3 and 6 months, objective confirmation at end of course.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 Taken from the qualitative-marker bullet list at ER lines 479–485.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All seven ER bullets appear as qualitative_item_1 through qualitative_item_7 in the same order.

Issues 21/08/2026 07:12

Pass rate 100.00%. No issues found.

Issues 21/08/2026 07:07

  1. 4.5 — Sheet exceeds one A4 page: The decision-gate block carries 16 full-length items (7 contraindications, 9 interactions), with the Key Interactions column alone running roughly 20 wrapped lines in a half-width 9.5pt column; combined with a 4-line At-A-Glance, a 3-line action_2_sub (line 466), 7 tier lines, 7 monitoring rows and 7 qualitative items, the sheet overruns the one-page budget rather than being condensed to it.

Fixes 21/08/2026 07:07

  1. 4.5 — At-A-Glance condensed: Trimmed at_a_glance from 59 to 52 words by dropping the redundant “acts only where it is placed” clause, which “barely crosses skin” already conveys.
  2. 4.5 — Interaction example lists trimmed: Cut each of the nine caution_items parentheticals from three or four named drugs to two (e.g. “(adapalene, tretinoin, tazarotene)” → “(adapalene, tretinoin)”), preserving every ER bold label and verdict verbatim.
  3. 4.5 — Contraindication items shortened: Condensed four stop_items — “leave-on skin or hair products” → “leave-on skin or hair use”, “nipple or areolar application” → “nipple or areolar use”, the microneedling/peel/laser/IPL clause → “freshly resurfaced skin (peel, laser, microneedling)”, and “Inside the eye” → “In the eye”.
  4. 4.5 — Protocol sub-cell trimmed: Reduced action_2_sub from three rendered lines to one by dropping the “equal efficacy and less irritation” rationale, leaving “Between the toes for four weeks; 25% preferred to 50%.”
  5. 4.5 — Monitoring cells tightened: Shortened marker_7_target to “…clear reduction vs baseline by week 4” and recast monitoring_cadence using parenthetical site lists instead of repeated “for … use” phrasing.
  6. 4.5 — Qualitative items shortened: Trimmed qualitative_item_1 and qualitative_item_3 to single lines (“…whether it settles or intensifies”; “Itch persisting after washing off, distinguishing sensitisation from irritation”).

Issues 21/08/2026 07:00

  1. 10.4 — Athlete’s foot rationale truncated: action_2_sub at line 467 reads “25% preferred to 50% for lower irritation”, omitting the ER’s stated equivalence of efficacy (ER line 378), which leaves the impression that the lower concentration trades effect for tolerability.

Fixes 21/08/2026 07:00

  1. 10.4 — Athlete’s foot rationale truncated: Changed action_2_sub from “25% preferred to 50% for lower irritation” to “25% preferred to 50%, equal efficacy and less irritation”, restoring the ER’s stated equivalence of efficacy (ER line 378).

Issues 21/08/2026 06:55

  1. 9.2 — Two ER interactions omitted: The Key Interactions gate carries only 7 of the 9 non-contraindication interaction bullets; “Oral prescription medicines (CYP3A4 substrates such as atorvastatin, midazolam, tacrolimus)” (ER line 328) and “Supplements taken by mouth (zinc, omega-3 fatty acids, oral probiotics)” (ER line 332) are dropped entirely.

Fixes 21/08/2026 06:55

  1. 9.2 — Two ER interactions omitted: Added the two missing non-contraindication interaction bullets to the Key Interactions gate — “Oral prescription medicines (atorvastatin, midazolam, tacrolimus): No established interaction from topical use” and “Supplements taken by mouth (zinc, omega-3, oral probiotics): No documented interaction” — bringing the gate to all 9 ER entries.

Issues 21/08/2026 06:48

  1. 4.5 — Sheet overruns one A4 page: The populated QRS renders well beyond a single A4 page; the Monitoring table (lines 667-766), both decision gates (lines 564-618), the Qualitative Assessment list (lines 781-815) and the Protocol sub-lines (lines 454-486) carry multi-line entries that were not condensed to the per-section budget.

Fixes 21/08/2026 06:48

  1. 4.5 — Protocol sub-lines condensed: Shortened all three action sub-lines, e.g. action_2_sub from “Between the toes for four weeks; 25% preferred over 50%, equivalent efficacy with lower irritation.” to “Between the toes for four weeks; 25% preferred to 50% for lower irritation.”
  2. 4.5 — Contraindication items tightened: Trimmed five of the seven stop items, e.g. the barrier-disruption entry from “skin freshly treated by a barrier-disrupting procedure (microneedling, chemical peel, laser resurfacing, intense pulsed light)” to “skin freshly treated by microneedling, peel, laser or intense pulsed light”; all qualifiers retained.
  3. 4.5 — Interaction parentheticals shortened: Reduced the example-drug lists in five caution items (dropping the duplicated “benzoyl peroxide”, and shortening “topical niacinamide, oral zinc, oral omega-3, topical ivermectin” to “niacinamide, zinc, omega-3, ivermectin”) without dropping any item.
  4. 4.5 — Monitoring rows compressed: Shortened marker names, targets and rationales across six of the seven rows, e.g. “Relevant only if unexplained breast tissue develops during use” to “Only if unexplained breast tissue develops” and “50% or greater reduction by week 12” to “≥50% reduction by week 12”.
  5. 4.5 — Qualitative items and cadence trimmed: Condensed three qualitative entries (e.g. “Itch that persists after the product is washed off, which distinguishes sensitisation from simple irritation” to “Itch persisting after the product is washed off, distinguishing sensitisation from irritation”) and tightened the cadence line.

Issues 21/08/2026 06:40

  1. 1.3 — At-A-Glance strengthens hedged claims: [at_a_glance] (lines 434–437) drops the ER’s hedges — “no plausible role as a longevity compound” (ER line 507) becomes “no role”, and “produces a lasting allergy in a small but real fraction of users” (ER line 511) becomes “produces lasting allergy”.
  2. 4.5 / 2.8 — Sheet exceeds one-page budget: 777 words of visible body text overflow a single A4 page; the long-form cells at lines 455–458 ([action_1_sub]), 758–761 ([marker_7_target]) and 773–777 ([monitoring_cadence]) carry condensable bulk.
  3. 2.8 — Redundant contraindication item: [stop_items] item 8 (lines 580–583) restates “freshly resurfaced skin” already covered by item 5 (line 574), consuming budget without adding a decision gate.

Fixes 21/08/2026 06:40

  1. 1.3 — At-A-Glance hedges restored: Rewrote [at_a_glance] to carry the ER’s own qualifiers — “no plausible longevity role” instead of “no role”, and “lasting allergy in a small but real fraction of users” instead of “lasting allergy” — while staying inside the 60-word budget at 59 words.
  2. 4.5 / 2.8 — Long-form cells condensed: Tightened [action_1_sub], [action_2_sub], [marker_7_target] and [monitoring_cadence] (e.g. cadence shortened from three clauses to two, scalp target from “change from the individual’s own baseline photographs, aiming for a clear reduction by week 4” to “clear reduction against baseline photographs by week 4”).
  3. 2.8 — Redundant contraindication merged: Folded the separate “Freshly treated skin after barrier-disrupting procedures” item into the existing eczema/open-wound item, reducing [stop_items] from eight entries to seven with no loss of ER-supported content.